EElephas develops a platform to predict how cancer patients will respond to immunotherapy. It runs ex vivo tests on fresh tumor biopsies, keeping the tissue alive and preserving the tumor microenvironment. The platform uses the Elephas Live Edge instrument to cut tissue precisely and a hydrogel called Live Protectâ„¢ to maintain viability. Treated samples are examined with multimodal microscopy and metabolic imaging to track immune activity, like T-cell activation and cancer cell killing, in real time. Results aiming to predict treatment efficacy appear within about 72 hours to help doctors choose or speed up effective therapies. The system is tumor-agnostic and serves two main groups: biopharma partners to accelerate drug development and clinicians for personalized treatment decisions.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$163.5M
Headquarters
Garrett Park, MD
Founded
2020
See people who can refer or advise you
Total Funding
$163.5M
Above
Industry Average
Funded Over
5 Rounds
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$163.5M
Headquarters
Garrett Park, MD
Founded
2020
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs